INTRODUCTION
============

Alopecia areata (AA) is characterized by non-scarring loss of scalp hair or the loss of hair on other body areas. It is divided into three forms, depending on hair loss severity. The mildest form of AA involves incomplete hair loss of the scalp, known as incomplete alopecia or alopecia *partialis* (AP). It can progress to alopecia *totalis* (AT), total hair loss of the scalp, or alopecia *universalis* (AU), entailing total loss of scalp hair and body hair.^[@r1]^ The disease affects 0.7% to 3.8% of patients seen in dermatology clinics worldwide, occurring in both genders, with extreme variation in age range and progression.^[@r2]^ In the past, metabolic, psychological and vascular abnormalities were seen as etiopathogenic factors.^[@r3]^ Nowadays, autoimmune and genetic factors are believed to be responsible for the disease.^[@r2]-[@r4]^

There is abundant evidence of the role played by immune mechanisms in AA, including the association with autoimmune diseases and the presence of circulating auto-antibodies.^[@r5]^ Thus, studies have been undertaken on the association between Human Leukocyte Antigen (HLA) and AA, suggesting that immunogenetic factors are involved in the disease\'s onset/development.^[@r2],[@r3],[@r6]^ The molecular basis of this association lies in the fact that HLA molecules bind to and present peptide antigens, derived from the organism itself, as well as peptides derived from etiologic agents for CD4 + and CD8 + lymphocytes.^[@r7],[@r8],[@r9]^ No studies on AA patients in the white Brazilian population have been conducted so far. Hence, the aim of this study was to investigate an association between AA and HLA class I/class II in white Brazilians.

OBJECTIVES
==========

Our aim was to investigate an association between AA and HLA class I/II in white Brazilians.

METHODS
=======

Patient selection
-----------------

This is a cross-sectional study of 33 white, Brazilian patients seen by dermatologists at the Dermatology Ambulatory of the Presidente Prudente Regional Hospital, São Paulo State, Brazil. One hundred and twelve healthy, white, Brazilian individuals with no history of AA were selected for the control group. They were matched with patients by gender, age and ethnic group. Patients answered an epidemiological questionnaire, providing information on: their age, gender, ethnicity, AA type (AP, AT and AU), age at AA onset (early onset: \< 16 years, late onset: ≥ 16 years), associated diseases such as thyroid diseases, diabetes, systemic lupus erythematosus, and personal and family history (we looked for evidence of AA in patients with relatives up to the third degree).

Determination of laboratory markers associated with autoimmune diseases
-----------------------------------------------------------------------

The association between AA and some of the more prevalent markers of autoimmune diseases was investigated. IgE antibodies were determined by chemiluminescence; antinucleus antibodies (ANA) were determined by immunofluorescence; while thyroid stimulant hormone (TSH), T4 and anti-thyroglobulin (anti-TG) were determined by electrochemiluminescence, in accordance with the manufacturer\'s instructions.

HLA typing
----------

Blood samples (5ml) were collected from patients and controls to determine HLA specificities (low/medium resolution). The blood was stored in tubes containing EDTA and sent to Maringá State University\'s Immunogenetic Laboratory, Maringá, Paraná, Brazil.

Genomic DNA was extracted through the column extraction technique using the Biopur^®^ Kit (Biometrix, Curitiba, PR, Brazil), following the manufacturer\'s instructions. HLA typing was performed with the PCR-SSO RELI technique (Dynal RELI^™^ SSO Carlsbad, CA, United States) for HLA-A, B and DRB1 genes, and SSO Luminex^®^ (One Lambda, Canoga Park, CA, USA) or HLA-C, DQA1 and DQB1 genes.

This study was registered and approved by the University of Oeste Paulista\'s ethics committee for research involving human subjects, under Number 045/OL/2009, Presidente Prudente, São Paulo State, Brazil. All participants signed an informed consent.

Statistical analysis
--------------------

Allele frequencies were obtained by direct counting and compared by 2X2 contingency tables using the chi-square test and Fisher\'s exact test. Only P values ​​\< 0.05 were significant. Significant P values ​​were corrected by the number of specificities tested at each locus (Pc; Bonferroni correction). Statistical analyses were carried out using the SISA statistics software (<http://www.quantitativeskills.com/sisa/>). The Hardy-Weinberg equilibrium was calculated through the Arlequin software.

RESULTS
=======

Patients characteristics
------------------------

The following patient characteristics are described in [Table 1](#t1){ref-type="table"}: age, gender at the onset, AA form, number of episodes, presence of associated diseases and family history. Most patients were men aged over 16, with no familial history of the disease. There was a prevalence of *partialis* AA with no recurrent episodes, and no significant differences between patients and control groups regarding age and gender. The sample population exhibited the Hardy-Weinberg equilibrium. Among the onset associated diseases reported by patients, the presence of Hashimoto thyroiditis was significantly higher in patients than in controls (14% vs. 1.8%, P=0.001). Laboratory markers of auto-immune diseases showed no differences in ANA or IgE levels in AA patients compared with controls, while TSH, T4 and anti-TG all appeared at normal levels in both groups (data not shown).

###### 

Clinical characteristics of 33 patients with alopecia areata and 112 controls, seen by dermatologists at the Dermatology Ambulatory of the Presidente Prudente Regional Hospital, São Paulo State, Brazil

  Clinical Parameters   Patients n=33   Controls n=112
  --------------------- --------------- ----------------
  Age (means±SD)        36.70±18.0      31.67±13.86
  Gender (%                             
  Male                  17 (51.2)       49 (43.7)
  Female                16 (48.5)       63 (56.3)
  AA type                               
  AP                    24 (72.7)       \-
  AT                    4 (12.1)        \-
  AU                    5 (15.2)        \-
  Episodes                              
  Single                12 (27.4)       \-
  Recurrent             21 (63.6)       \-
  Associated diseases                   
  Presence              7 (21.2)        \-
  Absence               26 (78.8)       \-
  Family                cases            
  Presence              7 (21.2)        \-
  Absence               31 (93.9)       \-

AA= alopecia areata; AP= alopecia partialis AT= alopecia totalis and AU= alopecia universalis

HLA class I
-----------

[Table 2](#t2){ref-type="table"} compares the frequency of HLA class I in patients and controls. Patients demonstrated a higher frequency of HLA-B\*40, HLA-B\*45, HLA-B\*53 and HLA-C\*04 than controls, although P was not significant after Bonferroni\'s correction: (HLA-B\*40 P = 0.02; Pc=0.56, OR=3.63; 95%; CI=1.13 to 11.67); (HLA-B\*45, P=0.01; Pc=0.28, OR=6.04; 95%; CI = 1.40 to 25.98); (HLA-B\*53 P = 0.03; Pc = 0.84, OR = 10.62; 95%; CI = 1.09 to 103.86); (HLA-C\*04; P = 0.04; Pc = 0.56; OR = 2.01; 95%; CI = 1.03 to 3 , 90). No statistical differences were observed for the locus A specificities (p\>0.05).

###### 

Distribution of HLA class I specificities in 33 AA patients and 112 controls, seen at the Dermatology Ambulatory of the Presidente Prudente Regional Hospital, São Paulo State, Brazil

  HLA-A                  HLA-B          HLA - C                                                                                                                          
  ----------- ---------- ---------- --- --------------------------------------------- ---------- ---------- --- --------------------------------------------- ---------- ----------
  **A\*01**   05(7.6)    20(8.9)        **B\*07**                                     07(10.6)   22(9.8)        **C\*01**                                     00(0.0)    07(3.1)
  **A\*02**   19(28.8)   61(27.2)       **B\*08**                                     02(3.0)    14(6.2)        **C\*02**                                     05(7.6)    14(6.2)
  **A\*03**   08(12.1)   26(11.6)       **B\*13**                                     00(0.0)    03(1.3)        **C\*03**                                     07(10.6)   20(8.9)
  **A\*11**   03(4.5)    09(4.0)        **B\*14**                                     01(1.5)    16(7.1)        **C\*04^[d](#TFN06){ref-type="table-fn"}^**   17(25.8)   33(14.7)
  **A\*23**   03(4.5)    10(4.4)        **B\*15**                                     05(7.6)    14(6.2)        **C\*05**                                     04(6.1)    05(2.2)
  **A\*24**   07(10.6)   24(10.7)       **B\*18**                                     03(4.5)    17(7.6)        **C\*06**                                     01(1.5)    14(6.2)
  **A\*25**   01(1.5)    05(2.2)        **B\*27**                                     00(0.0)    01(0.4)        **C\*07**                                     16(24.2)   61(27.2)
  **A\*26**   01(1.5)    11(4.9)        **B\*35**                                     10(15.1)   31(13.8)       **C\*08**                                     01(1.5)    14(6.2)
  **A\*29**   03(4.5)    17(7.6)        **B\*37**                                     00(0.0)    04(1.8)        **C\*12**                                     05(7.6)    21(9.4)
  **A\*30**   04(6.1)    05(2.2)        **B\*38**                                     02(3.0)    07(3.1)        **C\*14**                                     00(0.0)    09(4.0)
  **A\*31**   03(4.5)    13(5.8)        **B\*39**                                     02(3.0)    07(3.1)        **C\*15**                                     04(6.1)    09(4.0)
  **A\*32**   04(6.1)    04(1.8)        **B\*40^[a](#TFN03){ref-type="table-fn"}^**   06(9.1)    06(2.7)        **C\*16**                                     04(6.1)    14(6.2)
  **A\*33**   01(1.5)    04(1.8)        **B\*41**                                     00(0.0)    02(0.9)        **C\*17**                                     01(1.5)    01(0.4)
  **A\*66**   00(0.0)    02(0.9)        **B\*42**                                     01(1.5)    01(0.4)        **C\*18**                                     01(1.5)    02(0.9)
  **A\*68**   03(4.5)    11(4.9)        **B\*44**                                     05(7.6)    27(12.0)                                                                 
  **A\*69**   00(0.0)    01(0.4)        **B\*45^[b](#TFN04){ref-type="table-fn"}^**   05(7.6)    03(1.3)                                                                  
  **A\*74**   01(1.5)    01(0.4)        **B\*47**                                     00(0.0)    01(0.4)                                                                  
                                        **B\*48**                                     00(0.0)    02(0.9)                                                                  
                                        **B\*49**                                     01(1.5)    05(2.2)                                                                  
                                        **B\*50**                                     00(0.0)    04(1.8)                                                                  
                                        **B\*51**                                     07(10.6)   22(9.8)                                                                  
                                        **B\*52**                                     01(1.5)    02(0.9)                                                                  
                                        **B\*53^[c](#TFN05){ref-type="table-fn"}^**   03(4.5)    01(0.4)                                                                  
                                        **B\*55**                                     00(0.0)    03(1.3)                                                                  
                                        **B\*56**                                     00(0.0)    02(0.9)                                                                  
                                        **B\*57**                                     02(3.0)    03(1.3)                                                                  
                                        **B\*58**                                     03(4.5)    03(1.3)                                                                  
                                        **B\*78**                                     00(0.0)    01(0.4)                                                                  

n= number of specificities; (f)= frequency of specificities; OR= odds ratio; CI= confidence interval; Pc= P corrected;

HLA-B\*40: 9.1 vs 2.7; P=0.02; PC=0.56; OR= 3.63; 95%; CI= 1.13-11.67.

HLA-B\*45: 7.6 vs 1.3; P=0.01; PC=0.28; OR= 6.04; 95%; CI= 1.40-25.98.

HLA-B\*53: 4.5 vs 0.4; P=0.03; PC=0.84; OR=10.62; 95%; CI=1.09-103.86.

HLA-C\*04: 25.8 vs 14.7; P=0.04; PC=0.56; OR=2.01; 95%; CI=1.03-3.90.

HLA class II
------------

[Table 3](#t3){ref-type="table"} displays the results for HLA class II. Only HLA-DRB1\*07 showed statistical significance; nevertheless, it was more frequent in controls than in patients (P=0.04; Pc=0.52; OR=0.29; 95%; CI=0.07 to 1.25). Once again, P was not significant after Bonferroni\'s correction.

###### 

Distribution of HLA class II specificities in 33 AA patients and 112 controls, seen at the Dermatology Ambulatory of the Presidente Prudente Regional Hospital, São Paulo State, Brazil

  Allele Group                                     Patients n(f)   Controls n(f)   Alleles        Patients n(f)   Controls n(f)
  ------------------------------------------------ --------------- --------------- -------------- --------------- ---------------
  **DRB1**                                                                         **DQA1**                        
  **DRB1\*01**                                     06(9.1)         20(8.9)         **DQA1\*01**   31(46.9)        34(50.0)
  **DRB1\*03**                                     06(9.1)         22(9.8)         **DQA1\*02**   02(3.0)         06(8.8)
  **DRB1\*04**                                     08(12.1)        25(11.2)        **DQA1\*03**   09(13.6)        06(8.8)
  **DRB1\*07^[a](#TFN08){ref-type="table-fn"}^**   02(3.0)         22(9.8)         **DQA1\*04**   03(4.5)         03(4.4)
  **DRB1\*08**                                     04(6.1)         14(6.2)         **DQA1\*05**   21(31.8)        19(27.9)
  **DRB1\*09**                                     01(1.5)         03(1.3)                                         
  **DRB1\*10**                                     01(1.5)         06(2.7)         **DQB1**                        
  **DRB1\*11**                                     13(19.7)        35(15.6)        **DQB1\*02**   08(12.1)        15(22.1)
  **DRB1\*12**                                     01(1.5)         05(2.2)         **DQB1\*03**   25(37.9)        16(23.5)
  **DRB1\*13**                                     12(18.2)        25(11.2)        **DQB1\*04**   02(3.0)         03(4.4)
  **DRB1\*14**                                     01(1.5)         12(5.4)         **DQB1\*05**   14(21.2)        20(29.4)
  **DRB1\*15**                                     06(9.1)         26(11.6)        **DQB1\*06**   17(25.8)        14(20.6)
  **DRB1\*16**                                     05(7.6)         09(4.0)                                         

n= number of specificities; (f)= frequency of specificities; OR= odds ratio CI= confidence of interval; Pc= P corrected;

HLA-DRB1\*07: 3.0 vs 9.8; P=0.04; PC=0.52; OR= 0.29; 95%; CI= 0.07-1.25.

DISCUSSION
==========

AA is considered a disease with a broad spectrum of clinical features and variable age of onset. Genome-wide associations have shown that the disease is strongly linked to Major Histocompatibility Complex (MHC), although associated loci outside HLA have also been implicated in AA\'s pathogenesis.^[@r10]^ This study describes the distribution of HLA class I and II in white AA Brazilian patients. Comparing AA and control patients, there was no statistical difference between HLA class I and II allele distribution after Bonferroni\'s correction.

The role of HLA class II genes in the pathogenesis of AA was overwhelmingly highlighted in the literature.^[@r7],[@r10]^ In this study, only HLA-DRB1\*07 exhibited a statistical significance; nevertheless, it was more frequent in controls than in patients (P=0.04), although P was not significant after correction. Recently, a wide-genome meta-analysis examined a total of 2,489 AA patients and 5,287 controls, identifying four variants in HLA-DRA and HLA-DRB1 genes. The authors demonstrated the pivotal role of HLA class II genes and particularly of HLA-DRB1 in the etiopathogenic pathogenesis of AA.^[@r10]^ Our findings are different from those of some studies conducted in AA patients, which found both increased and decreased specificity in DRB1 genes associated with AA. In Turkey, Akar et al. observed a significant decrease in DRB1\*03 specificity - but an increase in DRB1\*04 specificity - in individuals affected by AA, depending on the intensity of hair loss.^[@r9]^ Furthermore, a study carried out in California by Colombe et al. uncovered increased levels of DRB1\*11:04 and DRB1\*04:01 alleles; however, the latter was high only in the AT/AU group, suggesting that in the population analyzed, this allele may indicate a more severe AA genetic susceptibility.^[@r11]^

This study found no association between DQ class II genes and AA. Significant increases in allele frequencies of HLA-DQA1\*01:04, DQB1\*06:04 and DQB1\*06:06 were described by Xiao et al. in Chinese patients, both in early- and late-onset disease.^[@r12]^ In Turkey, a significant increase in HLA-DQB01\*03 was identified compared with controls, leading to the conclusion that DQB1\*03 is a general marker of AA susceptibility in the country\'s population.^[@r9]^ Similar results were described in North Americans.^[@r11]^ Importantly, it was only for DQB1\*06:04 and DQB1\*06:06 in Chinese patients that the association with AA remained significant after Bonferroni\'s correction.^[@r12]^

Recently, an association was suggested between a new MHC class II candidate gene and AA development. Using exome sequencing, it was suggested in a Korean population diagnosed with AU, the involvement of HLA-DRB5. The HLA-DRB5 genes encode the class II MHC complex and are involved in antigen emergence by antigen-presenting cells. Further, the gene is related in several autoimmune diseases, such as multiple sclerosis, systemic sclerosis and rheumatic heart disease.^[@r13]^

Studies on HLA class I molecules are scarce and have yielded controversial results. In this study, no statistical differences were observed for the locus A specificities (p\>0.05). As highlighted for class II HLA genes, the results are different from those of other populations. Xiao et al.^[@r12]^ observed significantly increased frequencies for HLA-A\*02 and HLA-A\*03 in a study with Chinese patients, whereas in the Turkish sample, significance was only identified for HLA-A\*01.^[@r3]^ Regarding HLA-B, we found a higher frequency of HLA-B\*40, HLA-B\*45, HLA-B\*53 compared with controls, but, as with HLA class II genes, no statistical significance was found after Bonferroni\'s correction. The Turkish sample revealed significance for HLA- B\*62^[@r3]^, while in Chinese patients, increased frequencies were found for HLA-B\*17, B\*18 and B\*52. However, in both studies, no statistical differences remained following Bonferroni\'s correction.^[@r12]^ As for HLA-C, few published data are available. In our sample, only the HLA-C\*04 specificity was more frequent in patients than in controls before Bonferroni\'s correction. In Chinese individuals, Xiao et al. identified an association between AA and HLA-C\*07:04.^[@r12],[@r14]^ In both cases, similarly to our data, no significant statistical differences were found after Bonferroni\'s correction. Recently, in a Japanese population of 157 individuals with AA, a strong association with C\*04:01 and C\*15:02 was described.^[@r15]^ The variability concerning class I and class II gene specificities in AA patients of different countries could be attributed to the populations\' various genetic predispositions, as well as the influence of different behaviors, environmental and ethnic factors.^[@r10]^

Our study is limited because of the low number of patients due to difficulties in selecting AA patients and controls matched by ethnicity, gender and age. The cornerstone ethnic and racial composition of Brazil\'s population results from a confluence of many different ethnic backgrounds: indigenous peoples, black Africans, Portuguese colonizers, and subsequent waves of Europeans, Arabs, Japanese, as well as people from other Asian and South American countries. According to the Brazilian Institute of Geography and Statistic (IBGE), in 2010, Brazil\'s population was composed as follows: 47.7% white, 7.6% black, 43.1% brown or \"*pardos*\", 1% yellow and 0.4% indigenous.^[@r16]^

AA has been linked to autoimmune diseases, while significant associations with different comorbidities have been made, including: vitiligo, lupus erythematosus, psoriasis, atopic dermatitis, type I and type II diabetes, autoimmune thyroid disease, Down syndrome and allergic rhinitis.^[@r10],[@r17]^ In this study, only Hashimoto thyroiditis was significantly higher in patients compared with controls (P=0.007).

CONCLUSION
==========

The development of AA does not seem to be strongly associated with HLA in white Brazilians, nor with susceptibility or resistance. Our data did not confirm the previous findings in the literature. However, most of the AA/HLA gene associations were carried out in populations with little or no miscegenation, unlike the Brazilian population, thus leading to strong genetic variability, which could explain the data discrepancies/inconsistencies found. The study\'s small sample size is its main shortcoming; thus, further studies with larger population samples are recommended.
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